Submission to Pharmac to call for a revision of CLL treatment decision

Dr Neil Gram writes on behalf of CLL patients to ask Pharmac to revise the decision to fund only venetoclax for the treatment of CLL, by funding ibrutinib as an essential treatment for CLL, in addition to venetoclax. While we welcome the fact that a new era treatment for CLL has at last been funded, we have serious concerns about the limitations of the chosen medicine and its inability to meet the needs of all CLL patients, in particular those with severe CLL.

Click here to view the letter sent to Pharmac on 12 September 2019